BioCryst director Kenneth B. Lee, Jr. to retire from Board on Dec 31, 2023

BIOCRYST PHARMACEUTICALS INC

Lee notified company Nov 28, 2023 of retirement effective Dec 31, 2023.
He served as Audit Committee Chair and Finance Committee member.
Lee cited no disagreement with Board or management regarding company operations.
Lee had been a Board member for 12 years.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Kenneth B. Lee, Jr.

Director

BCRX · BIOCRYST PHARMACEUTICALS INC

Effective: 2023-12-31
Filed: December 1, 2023, 6:59 PM ET

On November 28, 2023, Kenneth B. Lee, Jr. notified BioCryst Pharmaceuticals, Inc. (the “Company”) of his intention to retire from the Board of Directors of the Company (the “Board”), effective December 31, 2023.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Kenneth B. Lee, Jr. departed as Director at BIOCRYST PHARMACEUTICALS INC.

Action: retire
Role: Director

Exact text from the filing

On November 28, 2023, Kenneth B. Lee, Jr. notified BioCryst Pharmaceuticals, Inc. (the “Company”) of his intention to retire from the Board of Directors of the Company (the “Board”), effective December 31, 2023.

View on SEC.gov

BIOCRYST PHARMACEUTICALS INC filing history →

Source: SEC EDGAR

accession 0001171843-23-007377

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.